Rocketvax AG

The company brings together both scientific and operational expertise from various institutions in Switzerland and Germany and aims to become a world leading centre of excellence for novel vaccine development. RocketVax has its foundation in the ties between Swiss Rockets AG, a Swiss incubator and accelerator for startups with innovative therapies, and a team of expert scientists from the Universities of Basel and Zurich, the ETH Zurich, the University Hospital Basel and the Swiss Tropical and Public Health Institute in Basel, and Gigabases Switzerland AG, a spinoff of ETH Zurich. Starting with the innovative concept of a live, single-cycle vaccine against SARS-CoV-2, Rocketvax’ portfolio was diversified by acquiring a platform encompassing multiple technologies for the generation of live-attenuated vaccines. RocketVax has partnered with a group of Swiss and internationally recognized teams of virologists and biochemists from the Swiss Federal Institute of Virology and Immunology, the Universities of Bern and Geneva, the Freie Universität Berlin and the Federal Institute for Animal Health of Germany, the Friedrich Loeffler Institute. At RocketVax, we use proprietary molecular biology technologies to develop novel vaccines for infectious diseases like Covid-19, cancer, and auto-immune-disorders. Several vaccine candidates in our pipeline are being developed and include the original live, single-cycle virus vaccine as well as live-attenuated vaccines against SARS-CoV-2 and a vaccine candidate against cancer.